📣 VC round data is live. Check it out!

CeriBell Valuation Multiples

Discover revenue and EBITDA valuation multiples for CeriBell and similar public comparables like Sunmax Biotechnology, Lumibird, Nanosonics, Advanced Medical Solutions Group and more.

CeriBell Overview

About CeriBell

CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.


Founded

2014

HQ

United States

Employees

327

Financials (LTM)

Revenue: $100M
EBITDA: ($54M)

EV

$545M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CeriBell Financials

CeriBell reported last 12-month revenue of $100M and negative EBITDA of ($54M).

In the same LTM period, CeriBell generated $87M in gross profit, ($54M) in EBITDA losses, and had net loss of ($58M).

Revenue (LTM)


CeriBell P&L

In the most recent fiscal year, CeriBell reported revenue of $89M and EBITDA of ($50M).

CeriBell is unprofitable as of last fiscal year, with gross margin of 88%, EBITDA margin of (56%), and net margin of (60%).

See analyst estimates for CeriBell
LTMLast FY202320242025202620272028
Revenue$100M$89M$45M$65M$89M
Gross Profit$87M$78M$38M$57M$78M
Gross Margin87%88%84%87%88%
EBITDA($54M)($50M)($27M)($37M)($50M)
EBITDA Margin(54%)(56%)(59%)(57%)(56%)
EBIT Margin(63%)(66%)(66%)(61%)(66%)
Net Profit($58M)($53M)($29M)($40M)($53M)
Net Margin(59%)(60%)(65%)(62%)(60%)

Financial data powered by Morningstar, Inc.

CeriBell Stock Performance

CeriBell has current market cap of $664M, and enterprise value of $545M.

Market Cap Evolution


CeriBell's stock price is $17.50.

CeriBell share price decreased by 5.0% in the last 30 days, and by 5.4% in the last year.

CeriBell has an EPS (earnings per share) of $-1.41.

See more trading valuation data for CeriBell
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$545M$664M-0.6%-5.0%-4.5%-5.4%$-1.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CeriBell Valuation Multiples

CeriBell trades at 5.5x EV/Revenue multiple, and (10.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for CeriBell

EV / Revenue (LTM)


CeriBell Financial Valuation Multiples

As of June 4, 2026, CeriBell has market cap of $664M and EV of $545M.

CeriBell has a P/E ratio of (11.4x).

LTMLast FY202320242025202620272028
EV/Revenue5.5x6.1x12.1x8.3x6.1x
EV/EBITDA(10.2x)(10.9x)(20.6x)(14.6x)(10.9x)
EV/EBIT(8.7x)(9.3x)(18.1x)(13.7x)(9.3x)
EV/Gross Profit6.3x7.0x14.3x9.6x7.0x
P/E(11.4x)(12.4x)(22.5x)(16.4x)(12.4x)
EV/FCF(11.8x)(13.6x)(18.1x)(15.0x)(13.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CeriBell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CeriBell Margins & Growth Rates

CeriBell grew revenue by 28% and EBITDA by 12% in the last fiscal year.

In the most recent fiscal year, CeriBell reported gross margin of 88%, EBITDA margin of (56%), and net margin of (60%).

See estimated margins and future growth rates for CeriBell

CeriBell Margins

Last FY202420252026202720282029
Gross Margin88%87%88%87%
EBITDA Margin(56%)(57%)(56%)(49%)
EBIT Margin(66%)(61%)(66%)(60%)
Net Margin(60%)(62%)(60%)(57%)
FCF Margin(45%)(56%)(47%)(48%)

CeriBell Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth28%45%36%28%
Gross Profit Growth27%49%38%27%
EBITDA Growth12%41%34%12%
EBIT Growth17%32%47%17%
Net Profit Growth22%37%32%22%
FCF Growth38%21%14%32%

Data powered by FactSet, Inc. and Morningstar, Inc.

CeriBell Operational KPIs

CeriBell's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

CeriBell's Rule of 40 is (21%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CeriBell's Rule of X is 20% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for CeriBell
LTMLast FY202320242025202620272028
Rule of 40(26%)(21%)---
Bessemer Rule of X16%20%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.4M---
S&M Expenses to Revenue80%82%86%75%82%
G&A Expenses to Revenue50%50%45%52%50%
R&D Expenses to Revenue22%21%20%21%21%
Opex to Revenue-153%151%147%153%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CeriBell Competitors

CeriBell competitors include Sunmax Biotechnology, Lumibird, Nanosonics, Advanced Medical Solutions Group, Synektik, SI-BONE, BrainsWay, SD Biosensor, Mesa Laboratories and Oculis Holding.

Most CeriBell public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sunmax Biotechnology9.8x-17.7x-
Lumibird2.9x2.9x15.0x13.9x
Nanosonics4.0x3.8x25.2x33.8x
Advanced Medical Solutions Group2.3x2.3x10.9x10.3x
Synektik2.8x2.5x11.3x9.8x
SI-BONE2.6x2.4x58.3x51.0x
BrainsWay10.3x9.2x55.0x57.3x
SD Biosensor1.0x-(1.0x)-

This data is available for Pro users. Sign up to see all CeriBell competitors and their valuation data.

Start Free Trial

CeriBell VC Funding History

Before going public, CeriBell raised $151M in total equity funding, across 4 rounds.

Last private valuation of CeriBell was $329M, after raising $50M in September 2022 from Ally Bridge Group.


CeriBell Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-22Series CAlly Bridge Group$50M$329MCeriBell, Inc. develops the Ceribell Rapid Response EEG System, a cloud-linked, portable electroencephalogram (EEG) platform designed for point-of-care brain monitoring to enable faster diagnosis of seizures and other neurological conditions like delirium in emergency departments and intensive care units. The technology uses machine learning to analyze brain waves, addressing the need for easier and quicker seizure triage, and has received FDA Breakthrough Device Designation for delirium detection as well as multiple 510(k) clearances since 2017. On September 21, 2022, CeriBell closed a $50 million equity financing round (reported as $49.4 million in some sources) led by Ally Bridge Group, with participation from existing shareholders, structured as an extension of its prior $53 million Series C round from April 2021, bringing the total Series C to $103 million. Post-money valuation stood at $328.64 million per company-submitted Certificate of Incorporation, with a pre-money valuation of $253 million; total funding raised to date approximately $153.6 million. Ally Bridge Group Partner Charles Chon highlighted the company's novel technology and commercial traction. CEO Jane Chao emphasized the system's impact on improving care for seizure patients and plans to expand commercially into more ICUs and EDs while developing solutions for additional neurological indications. The proceeds support ongoing commercial expansion, further product development, and team growth, with 23 positions open across departments at the time. The company continues advancing its platform, including machine learning enhancements for broader neurological applications.
Apr-21Series CLongitude Capital; RA Capital Management; Red Tree Venture Capital; Redmile Group; The Rise Fund$53M-Ceribell, Inc. is a Mountain View, CA-based company founded in 2014 that develops a point-of-care EEG system to make EEG widely available, more efficient, and cost-effective for diagnosing and treating neurological conditions, particularly seizures in critical care patients. The system received FDA 510(k) clearance in 2017 and is commercially available in the US. It features a non-invasive brain monitor with a disposable headset and AI-powered algorithms to detect hidden seizures rapidly. On April 29, 2021, Ceribell closed a $53 million Series C financing round co-led by Longitude Capital and The Rise Fund, with participation from new investors RA Capital Management, Redmile Group, and Red Tree Venture Capital. This followed a Series B round of $35 million in September 2018, also co-led by The Rise Fund. The funding aims to expand the seizure detection platform to more patients and hospitals to improve treatment, care standards, and health economics. Investors highlighted Ceribell's strong value in its groundbreaking point-of-care EEG technology, which has gained success among healthcare providers and represents a game-changing opportunity to improve patient care. By the time of later rounds, such as a $50 million Series C extension in 2022 led by Ally Bridge Group, Ceribell had added AI monitoring, partnered with pharma and hospitals, and treated over 100,000 patients across 500+ hospitals, reducing ICU stays. Ceribell later went public in October 2024, raising $180.3 million on Nasdaq under ticker CBLL at an implied valuation of $578 million, with a prior Series C-1 valuation of $328.64 million in September 2022.
Sep-18Series BLivaNova; Optimas Capital Partners Fund; The Rise Fund; UCB$35M-CeriBell, Inc., based in Mountain View, California, develops a portable, cloud-linked Rapid Response EEG system designed for faster diagnosis of seizures in ICU and ED patients, addressing limitations of traditional EEG systems that can take hours or days to deploy. The technology enables clinicians to make timely treatment decisions, reducing risks of overtreatment, undertreatment, long-term brain damage, or death, while lowering healthcare costs. On September 25-26, 2018, CeriBell completed a $35 million Series B financing round led by Optimas Capital Partners Fund and The Rise Fund (part of TPG Growth), with participation from LivaNova and Union Chimique Belge (UCB). The funds were intended to expand commercialization of the Ceribell platform. Optimas Capital, a Hong Kong-based growth-oriented fund focused on technology including medical devices, highlighted Ceribell's potential to transform seizure monitoring and improve patient outcomes. Subsequent rounds included a $50 million equity financing in December 2019 led by Ally Bridge Group as a Series C extension, $53 million Series C in April 2021 co-led by Longitude Capital and The Rise Fund with RA Capital Management, and a $50 million Series C in September 2022 also led by Ally Bridge Group, bringing total funding to around $138-153.6 million by 2022. CeriBell went public via IPO on October 11, 2024, on NASDAQ under ticker CBLL, raising $180.2 million at a $578 million implied valuation, with a prior Series C-1 post-money valuation of $328.64 million in September 2022.
May-17Series ADHVC; Shangbay Capital$13M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CeriBell

When was CeriBell founded?CeriBell was founded in 2014.
Where is CeriBell headquartered?CeriBell is headquartered in United States.
How many employees does CeriBell have?As of today, CeriBell has over 327 employees.
Who is the CEO of CeriBell?CeriBell's CEO is Xingjuan Chao.
Is CeriBell publicly listed?Yes, CeriBell is a public company listed on Nasdaq.
What is the stock symbol of CeriBell?CeriBell trades under CBLL ticker.
When did CeriBell go public?CeriBell went public in 2024.
Who are competitors of CeriBell?CeriBell main competitors include Sunmax Biotechnology, Lumibird, Nanosonics, Advanced Medical Solutions Group, Synektik, SI-BONE, BrainsWay, SD Biosensor, Mesa Laboratories, Oculis Holding.
What is the current market cap of CeriBell?CeriBell's current market cap is $664M.
What is the current revenue of CeriBell?CeriBell's last 12 months revenue is $100M.
What is the current revenue growth of CeriBell?CeriBell revenue growth (NTM/LTM) is 28%.
What is the current EV/Revenue multiple of CeriBell?Current revenue multiple of CeriBell is 5.5x.
Is CeriBell profitable?No, CeriBell is not profitable.
What is the current EBITDA of CeriBell?CeriBell has negative EBITDA and is not profitable.
What is CeriBell's EBITDA margin?CeriBell's last 12 months EBITDA margin is (54%).
What is the current EV/EBITDA multiple of CeriBell?Current EBITDA multiple of CeriBell is (10.2x).
What is the current FCF of CeriBell?CeriBell's last 12 months FCF is ($46M).
What is CeriBell's FCF margin?CeriBell's last 12 months FCF margin is (47%).
What is the current EV/FCF multiple of CeriBell?Current FCF multiple of CeriBell is (11.8x).
How many companies CeriBell has acquired to date?CeriBell hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies CeriBell has invested to date?CeriBell hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CeriBell

Lists including CeriBell

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial